NicOx SA

278 articles about NicOx SA

• NicOx SA Announces The Presentation Of NCX 667 Scientific Data At AOPT 2017

  2/21/2017

• NicOx SA Transfers Commercial Operations to New Company, Gets Minority Stake

  7/5/2016

• FDA Grants Priority Review For NicOx SA's AC-170 New Drug Application

  6/21/2016

• NicOx SA Submits New Drug Application For AC-170 To U.S. FDA

  4/20/2016

• Bausch & Lomb And NicOx SA Announce FDA Acceptance Of New Drug Application For Novel Glaucoma Candidate VESNEO (Latanoprostene Bunod)

  9/22/2015

• NicOx SA Gets Boost From Strong Prospects For Glaucoma Drug Vesneo

  9/25/2014

• NicOx SA Focuses U S. Operations On National Launches Of Sjo™ And Retnagene™ And Restructures RPS® Licensing Agreement

  7/10/2014

• NicOx SA Scoops Up Aciex Therapeutics In $120 Million Deal

  7/2/2014

• NicOx SA Launches Commercial Operations In Germany

  6/30/2014

• NicOx SA And Sequenom Inc. Announce The Launch Of Expanded Access To Retnagene™ Test Portfolio In The U.S.

  6/19/2014

• NicOx SA And Sequenom Inc. Announce The Launch Of Expanded Access To Retnagene™ Test Portfolio In The U.S.

  6/19/2014

• NicOx SA: Santen, Inc. Grants EuPharmed Extension Of Exclusive Rights To Distribute Cationorm® In Italy

  5/30/2014

• NicOx SA: Santen Grants Eupharmed Extension Of Exclusive Rights To Distribute Cationorm® In Italy

  5/28/2014

• NicOx SA: First Quarter 2014 Financial Information

  5/15/2014

• NicOx SA 2013 Financial Results And Business Update

  4/2/2014

• NicOx SA Launches Adenoplus® And Xailin™ Dry Eye Product Range In Europe

  3/17/2014

• NicOx SA To Re-Focus Naproxcinod On Duchenne Muscular Dystrophy

  2/14/2014

• NicOx SA Appoints Evelyne Nguyen As CFO

  2/4/2014

• Sequenom Inc. Laboratories Grants NicOx SA Exclusive Promotion And Marketing Rights For Its Retnagene™ AMD Test In North America

  1/17/2014

• Sequenom Inc. Laboratories Grants Nicox Exclusive Promotion And Marketing Rights For Its Retnagene™ AMD Test In North America

  1/16/2014